Antiepidermal growth-factor receptors do not benefit colorectal cancer patients with KRAS mutations. However, there is evidence that adding these agents to standard chemotherapy might be detrimental. Medscape Medical News
Can any of the biomarkers developed in recent years help us make difficult treatment decisions in colorectal and other GI cancers? Dr. Axel Grothey summarizes the latest news from ASCOŽ 2011. br / iMedscape Hematology-Oncology/i
Liver resection does not benefit patients with colorectal liver metastases if their celiac or para-aortic regional lymph nodes are involved, even if the disease responds to preoperative chemotherapy. Reuters Health Information
